How timing and sensory predictions are altered in people with schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants view an illusion where two moving squares collide and disappear while subtle timing perturbations (millisecond-scale accelerations and rebounds) are introduced during their trajectories. Neurotypical observers normally perceive a brief gap at collision because sensory predictions create a mismatch when contrast disappears, and this task measures that prediction error. The study compares responses from adults with schizophrenia to those of controls to see if patients are abnormally sensitive to trajectory changes. Behavioral responses to the illusion will be used to probe differences in sensory prediction and timing processing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female;
* Age between 18 and 60 inclusive;
* Subject having dated and signed the consent form prior to the start of any trial-related procedure (guardian or curator where applicable);
* Member of a social security scheme or beneficiary of such a scheme.

Exclusion Criteria:

* Psychoactive substance use disorders (as defined by the DSM-V) (Diagnostic and Statistical Manual-V);
* Use of benzodiazepines, hallucinogens (in the period preceding before inclusion, for a duration equivalent to 5 half-lives of the product) or cannabis (in the 2 months preceding inclusion);
* Neurological pathology or sequelae;
* Attention deficit hyperactivity disorder (ADHD);
* Borderline personality disorder;
* Disabling sensory disorders (visual acuity \<0.8);
* Person deprived of liberty or under court protection;
* Pregnant, parturient or breast-feeding women;
* Subjects in a period of exclusion defined by another clinical study.

Where it's running

• CHU Sainte Marguerite, APHM
  Marseille, France Recruiting
• Centre Hospitalier Drôme Vivarais
  Montéléger, France Recruiting

Study contacts

• Principal investigator: Anne Giersch, MD PhD — Institut National de la Santé Et de la Recherche Médicale, France
• Study coordinator: Anne Giersch, MD PhD
• Email: giersch@unistra.fr
• Phone: 0033 3 88 116471

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

• Neuronavigated rTMS for treatment-resistant auditory hallucinations

  We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.

  Recruiting Psychiatric University Hospital, Zurich · Zurich · NCT07856368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.